Advertisement
Canada markets open in 5 hours 8 minutes
  • S&P/TSX

    22,465.37
    +165.57 (+0.74%)
     
  • S&P 500

    5,308.13
    +4.86 (+0.09%)
     
  • DOW

    39,806.77
    -196.82 (-0.49%)
     
  • CAD/USD

    0.7333
    -0.0008 (-0.12%)
     
  • CRUDE OIL

    79.16
    -0.64 (-0.80%)
     
  • Bitcoin CAD

    96,746.31
    +5,493.85 (+6.02%)
     
  • CMC Crypto 200

    1,524.87
    +36.33 (+2.44%)
     
  • GOLD FUTURES

    2,422.70
    -15.80 (-0.65%)
     
  • RUSSELL 2000

    2,102.50
    +6.78 (+0.32%)
     
  • 10-Yr Bond

    4.4370
    +0.0170 (+0.38%)
     
  • NASDAQ futures

    18,749.50
    -13.50 (-0.07%)
     
  • VOLATILITY

    12.33
    +0.18 (+1.48%)
     
  • FTSE

    8,387.61
    -36.59 (-0.43%)
     
  • NIKKEI 225

    38,946.93
    -122.75 (-0.31%)
     
  • CAD/EUR

    0.6749
    -0.0007 (-0.10%)
     

Akebia Awaits FDA Word On Second Crack At Vadadustat

Akebia Awaits FDA Word On Second Crack At Vadadustat

The FDA, which turned away Akebia's initial application last March 2022, has a target action of Wednesday on the company's resubmission, which included safety data from tens of thousands of patients in Japan, where vadadustat was approved in mid-2020. Akebia has said it is prepping for a U.S. commercial launch of vadadustat in the second half if it gets an FDA green light.